Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Rupert Bauersachs"'
Autor:
Rupert Bauersachs, Walter Ageno, Gualberto Gussoni, Ander Cohen, Cecilia Becattini, Giancarlo Agnelli, Maria Cristina Vedovati, Menno V. Huisman
Publikováno v:
Thrombosis and Haemostasis
Thrombosis and Haemostasis. GEORG THIEME VERLAG KG
Thrombosis and Haemostasis. GEORG THIEME VERLAG KG
Background Direct oral anticoagulants are recommended for the treatment of cancer-associated thrombosis (CAT) as an alternative to low-molecular-weight heparin (LMWH), but an increased bleeding risk in patients with gastrointestinal cancer was report
Autor:
Ajay K. Kakkar, Rodney Hughes, Mark Levine, Anna Falanga, Rupert Bauersachs, Alex Kahney, John Wong, Gloria Kayani
Publikováno v:
The Oncologist
Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRO
Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment
Publikováno v:
Thrombosis research. 204
Pulmonary embolism (PE) is associated with adverse outcomes and substantial morbidity and mortality. Patients with PE often have renal impairment because of shared risk factors and close links between the renal and cardiovascular systems. Furthermore
Autor:
Anselm K. Gitt, Giancarlo Agnelli, Stefan N. Willich, Eva-Maria Fronk, Manuel Monreal, Rupert Bauersachs, Alexander T. Cohen, Peter Bramlage, Petra Laeis, Patrick Mismetti
Publikováno v:
Thrombosis Research. 157:181-188
Introduction The appropriate strategy for initiating oral anticoagulant (OAC) therapy after an acute venous thromboembolism (VTE) depends on the intermediate-term anticoagulant to be used. While heparin bridging to vitamin K antagonists (VKA) is requ
Autor:
Jan Beyer-Westendorf, Peter Verhamme, Anthony Maraveyas, Rupert Bauersachs, Jeffrey I. Weitz, Mark Crowther, Hanno Riess, Annie M. Young
Publikováno v:
Critical Reviews in Oncology/Hematology. 157:103125
Low-molecular-weight heparin (LMWH) therapy is recommended over vitamin K antagonists (VKAs) for the treatment of cancer-associated thrombosis (CAT) and extended therapy is recommended in those with active cancer to prevent recurrent thrombosis. Howe
Publikováno v:
Thrombosis Research, Vol. 151, No Suppl. 1 (2017) pp. S21-S29
Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to ca
Publikováno v:
Martínez-Zapata, M J, Mathioudakis, A, Mousa, S & Bauersachs, R 2017, ' Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer : A Systematic Review and Meta-Analysis ', Clinical and Applied Thrombosis / Hemostasis . https://doi.org/10.1177/1076029617696581
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding. Thus, long-term treatment with anticoagulants for secondary prevention is challenging. The objective of this review was to evaluate current evidence on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::521a7f4d8c8e04ead8f731f97d08ece9
https://doi.org/10.1177/1076029617696581
https://doi.org/10.1177/1076029617696581
Publikováno v:
La Presse Médicale
La Presse Médicale, Elsevier Masson, 2015, 44 (12 Pt 2), pp.e393-9. ⟨10.1016/j.lpm.2015.10.008⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (12 Pt 2), pp.e393-9. 〈10.1016/j.lpm.2015.10.008〉
La Presse Médicale, Elsevier Masson, 2015, 44 (12 Pt 2), pp.e393-9. ⟨10.1016/j.lpm.2015.10.008⟩
La Presse Médicale, Elsevier Masson, 2015, 44 (12 Pt 2), pp.e393-9. 〈10.1016/j.lpm.2015.10.008〉
International audience; The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs). There are currently three anti-Xa factors (rivaroxaban, apixaban, edoxaban) and one anti-IIa factor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2084845ecfba01b7c5c43fd2ef33c8ff
https://hal.univ-brest.fr/hal-01259804
https://hal.univ-brest.fr/hal-01259804
Autor:
Samson Fung, Eberhard Herchenhan, Thorsten Fischer, Michael Spannagl, Joachim W. Dudenhausen, Job Harenberg, Ulrich Geisen, A Faridi, Franz Keller, Rupert Bauersachs, Bettina Kemkes-Matthes, Christian J. Thaler, Helmut Schinzel
Publikováno v:
Thrombosis and Haemostasis. 98:1237-1245
SummaryWomen with a history of venous thromboembolism (VTE), thrombophilia or both may be at increased risk of thrombosis during pregnancy, but the optimal management strategy is not well defined in clinical guidelines because of limited trial data.
Autor:
Michael B. Streiff, M Beckers, Manuel Monreal, Mohammed H. Qari, Ajay K. Kakkar, Shaker A. Mousa, Barry M. Brenner, Rupert Bauersachs, Nissim Haim, Paolo Prandoni, Philippe Debourdeau, Anna Falanga, Martin H. Prins, Michel Marty, Alok A. Khorana, C. Baglin, Ingrid Pabinger, Konstantinos N. Syrigos, Dialina Brilhante, Mario Mandalà, Dominique Farge, Henri Bounameaux, Ramón Lecumberri, H. R. Büller, G T Gerotzafias, Simon Noble
Publikováno v:
Journal of Thrombosis and Haemostasis, Vol. 11, No 1 (2013) pp. 56-70
Journal of Thrombosis and Haemostasis, 11(1), 56-70. Wiley
Journal of Thrombosis and Haemostasis, 11(1), 56-70. Wiley
Summary. Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide. Objectives: To establish a common international consensus addressin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2bf2d3717be38b9bf609b87eb0f91d
http://hdl.handle.net/11391/1480953
http://hdl.handle.net/11391/1480953